Houghton PJ - Search Results

1

Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.

Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJ. Shen C, et al. Among authors: houghton pj. Cancer Res. 2013 Jun 1;73(11):3393-401. doi: 10.1158/0008-5472.CAN-12-4282. Epub 2013 Apr 30. Cancer Res. 2013. PMID: 23633493 Free PMC article.

2

Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.

Hosoi H, Dilling MB, Shikata T, Liu LN, Shu L, Ashmun RA, Germain GS, Abraham RT, Houghton PJ. Hosoi H, et al. Among authors: houghton pj. Cancer Res. 1999 Feb 15;59(4):886-94. Cancer Res. 1999. PMID: 10029080

3

p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.

Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. Huang S, et al. Among authors: houghton pj. Cancer Res. 2001 Apr 15;61(8):3373-81. Cancer Res. 2001. PMID: 11309295

4

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.

Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ. Thimmaiah KN, et al. Among authors: houghton pj. Cancer Res. 2003 Jan 15;63(2):364-74. Cancer Res. 2003. PMID: 12543789

5

IRS-1: auditing the effectiveness of mTOR inhibitors.

Easton JB, Kurmasheva RT, Houghton PJ. Easton JB, et al. Among authors: houghton pj. Cancer Cell. 2006 Mar;9(3):153-5. doi: 10.1016/j.ccr.2006.02.027. Cancer Cell. 2006. PMID: 16530700 Free article. Review.

6

Predicted mechanisms of resistance to mTOR inhibitors.

Kurmasheva RT, Huang S, Houghton PJ. Kurmasheva RT, et al. Among authors: houghton pj. Br J Cancer. 2006 Oct 23;95(8):955-60. doi: 10.1038/sj.bjc.6603353. Epub 2006 Sep 5. Br J Cancer. 2006. PMID: 16953237 Free PMC article. Review.

7

SK-NEP-1 and Rh1 are Ewing family tumor lines.

Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. Smith MA, et al. Among authors: houghton pj. Pediatr Blood Cancer. 2008 Mar;50(3):703-6. doi: 10.1002/pbc.21099. Pediatr Blood Cancer. 2008. PMID: 17154184

8

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ. Smith MA, et al. Among authors: houghton pj. Pediatr Blood Cancer. 2008 Jul;51(1):34-41. doi: 10.1002/pbc.21508. Pediatr Blood Cancer. 2008. PMID: 18260120

9

Molecular characterization of the pediatric preclinical testing panel.

Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ. Neale G, et al. Among authors: houghton pj. Clin Cancer Res. 2008 Jul 15;14(14):4572-83. doi: 10.1158/1078-0432.CCR-07-5090. Clin Cancer Res. 2008. PMID: 18628472 Free PMC article.

10

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.

Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA. Gorlick R, et al. Among authors: houghton pj. Pediatr Blood Cancer. 2009 Oct;53(4):594-8. doi: 10.1002/pbc.21989. Pediatr Blood Cancer. 2009. PMID: 19554571 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

591 results

Search Page

Filters